{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:07:43Z","timestamp":1763179663482,"version":"3.44.0"},"reference-count":41,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Opioids are known to come with some relatively benign side effects, not including their addictive potential. This review will look at some of the side effects that occur when patients, especially chronic pain patients, take opioids chronically. These side effects include both hyperalgesia and allodynia caused by opioids. Overdose and factors, including hyperalgesia and allodynia, that make a patient more likely to overdose, is the other topic that will be covered. Not much research has been done with human subjects regarding treatment of opioid induced hyperalgesia or allodynia, but some of this research will also be briefly explored throughout this review.<\/jats:p>","DOI":"10.5055\/jom.0891","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:43Z","timestamp":1755718483000},"page":"349-353","source":"Crossref","is-referenced-by-count":1,"title":["Hyperalgesia, allodynia, and eventual overdose: The problems with chronic opioid use"],"prefix":"10.5055","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5906-983X","authenticated-orcid":false,"given":"Steven","family":"Sochacki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"96919","doi-asserted-by":"crossref","unstructured":"Franklin GM, American Academy of Neurology: Opioids for chronic noncancer pain: A position paper of the American Academy of Neurology. Neurology. 2014; 83(14): 1277-1284. DOI: 10.1212\/WNL.0000000000000839.","DOI":"10.1212\/WNL.0000000000000839"},{"key":"96920","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, et al.: Provisional drug overdose death counts. National Center for Health Statistics. 2022. Available at https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drugoverdose-data.htm. Accessed May 6, 2025."},{"key":"96921","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Vanaparthy R, Atluri S, et al.: COVID-19 and the opioid epidemic: Two public health emergencies that intersect with chronic pain. Pain Ther. 2021; 10(1): 269-286. DOI: 10.1007\/s40122-021-00243-2.","DOI":"10.1007\/s40122-021-00243-2"},{"key":"96922","doi-asserted-by":"crossref","unstructured":"Gregorian RS Jr, Gasik A, Kwong WJ, et al.: Importance of side effects in opioid treatment: A trade-off analysis with patients and physicians. J Pain. 2010; 11(11): 1095-1108. DOI: 10.1016\/j.jpain.2010.02.007.","DOI":"10.1016\/j.jpain.2010.02.007"},{"key":"96923","doi-asserted-by":"crossref","unstructured":"Volkow ND, McLellan AT: Opioid abuse in chronic pain\u2013misconceptions and mitigation strategies. N Engl J Med. 2016; 374(13): 1253-1263. DOI: 10.1056\/NEJMra1507771.","DOI":"10.1056\/NEJMra1507771"},{"key":"96924","doi-asserted-by":"crossref","unstructured":"Chen L, Sein M, Vo T, et al.: Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag. 2014; 10(6): 383-393. DOI: 10.5055\/jom.2014.0235.","DOI":"10.5055\/jom.2014.0235"},{"key":"96925","doi-asserted-by":"crossref","unstructured":"Lee M, Silverman SM, Hansen H, et al.: A comprehensive review of opioid-induced hyperalgesia. Pain Phys. 2011; 14(2): 145-161.","DOI":"10.36076\/ppj.2011\/14\/145"},{"key":"96926","doi-asserted-by":"crossref","unstructured":"Silverman SM: Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Phys. 2009; 12(3): 679-684.","DOI":"10.36076\/ppj.2009\/12\/679"},{"key":"96927","doi-asserted-by":"crossref","unstructured":"Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994; 14(4): 2301-2312. DOI: 10.1523\/JNEUROSCI.14-04-02301.1994.","DOI":"10.1523\/JNEUROSCI.14-04-02301.1994"},{"key":"96928","doi-asserted-by":"crossref","unstructured":"Gardell LR, Wang R, Burgess SE, et al.: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002; 22(15): 6747-6755. DOI: 10.1523\/JNEUROSCI.22-15-06747.2002.","DOI":"10.1523\/JNEUROSCI.22-15-06747.2002"},{"key":"96929","doi-asserted-by":"crossref","unstructured":"Vanderah TW, Suenaga NM, Ossipov MH, et al.: Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001; 21(1): 279-286. DOI: 10.1523\/JNEUROSCI.21-01-00279.2001.","DOI":"10.1523\/JNEUROSCI.21-01-00279.2001"},{"key":"96930","doi-asserted-by":"crossref","unstructured":"Tompkins DA, Campbell CM: Opioid-induced hyperalgesia: Clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011; 15(2): 129-136. DOI: 10.1007\/s11916-010-0171-1.","DOI":"10.1007\/s11916-010-0171-1"},{"key":"96931","doi-asserted-by":"crossref","unstructured":"Compton P, Charuvastra VC, Ling W: Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend. 2001; 63(2): 139-146. DOI: 10.1016\/s0376-8716(00)00200-3.","DOI":"10.1016\/S0376-8716(00)00200-3"},{"key":"96932","doi-asserted-by":"crossref","unstructured":"Galer BS, Lee D, Ma T, et al.: MorphiDex (morphine sulfate\/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, doubleblind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain. 2005; 115(3): 284-295. DOI: 10.1016\/j.pain.2005.03.004.","DOI":"10.1016\/j.pain.2005.03.004"},{"key":"96933","doi-asserted-by":"crossref","unstructured":"Arout CA, Edens E, Petrakis IL, et al.: Targeting opioid-induced hyperalgesia in clinical treatment: Neurobiological considerations. CNS Drugs. 2015; 29(6): 465-486. DOI: 10.1007\/s40263-015-0255-x.","DOI":"10.1007\/s40263-015-0255-x"},{"key":"96934","doi-asserted-by":"crossref","unstructured":"Yalcin N, Uzun ST, Reisli R, et al.: A comparison of ketamine and paracetamol for preventing remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy. Int J Med Sci. 2012; 9(5): 327-333. DOI: 10.7150\/ijms.4222.","DOI":"10.7150\/ijms.4222"},{"key":"96935","doi-asserted-by":"crossref","unstructured":"Shaheed G, Manjooran AP, Reddy AJ, et al.: Low-dose naltrexone co-treatment in the prevention of opioid-induced hyperalgesia. Cureus. 2021; 13(9): e17667. DOI: 10.7759\/cureus.17667.","DOI":"10.7759\/cureus.17667"},{"key":"96936","unstructured":"Oaks Z, Stage A, Middleton B, et al.: Clinical utility of the cold pressor test: Evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med. 2018; 26: 197-206."},{"key":"96937","doi-asserted-by":"crossref","unstructured":"Jackson D, Singh S, Zhang-James Y, et al.: The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021; 12: 593842-16. DOI: 10.3389\/fpsyt.2021.593842.","DOI":"10.3389\/fpsyt.2021.593842"},{"key":"96938","doi-asserted-by":"crossref","unstructured":"Yi P, Pryzbylkowski P: Opioid induced hyperalgesia. Pain Med. 2015; 16(Suppl. 1): S32-S36. DOI: 10.1111\/pme.12914.","DOI":"10.1111\/pme.12914"},{"key":"96939","doi-asserted-by":"crossref","unstructured":"Hayes CJ, Painter JT: A comprehensive clinical review of opioid-induced allodynia: Discussion of the current evidence and clinical implications. J Opioid Manag. 2017; 13(2): 95-103. DOI: 10.5055\/jom.2017.0373.","DOI":"10.5055\/jom.2017.0373"},{"key":"96940","doi-asserted-by":"crossref","unstructured":"Arn\u00e9r S, Rawal N, Gustafsson LL: Clinical experience of long-term treatment with epidural and intrathecal opioids\u2014A nationwide survey. Acta Anaesthesiol Scand. 1988; 32(3): 253-259. DOI: 10.1111\/j.1399-6576.1988.tb02725.x.","DOI":"10.1111\/j.1399-6576.1988.tb02725.x"},{"key":"96941","doi-asserted-by":"crossref","unstructured":"Sj\u00f8gren P, Jensen NH, Jensen TS: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994; 59(2): 313-316. DOI: 10.1016\/0304-3959(94)90084-1.","DOI":"10.1016\/0304-3959(94)90084-1"},{"key":"96942","doi-asserted-by":"crossref","unstructured":"Trang T, Al-Hasani R, Salvemini D, et al.: Pain and poppies: The good, the bad, and the ugly of opioid analgesics. J Neurosci. 2015; 35(41): 13879-13888. DOI: 10.1523\/JNEUROSCI.2711-15.2015.","DOI":"10.1523\/JNEUROSCI.2711-15.2015"},{"key":"96943","doi-asserted-by":"crossref","unstructured":"Johnson JL, Rolan PE, Johnson ME, et al.: Codeine-induced hyperalgesia and allodynia: Investigating the role of glial activation. Transl Psychiatry. 2014; 4(11): e482-e482. DOI: 10.1038\/tp.2014.121.","DOI":"10.1038\/tp.2014.121"},{"key":"96944","doi-asserted-by":"crossref","unstructured":"Laughlin TM, Vanderah TW, Lashbrook J, et al.: Spinally administered dynorphin a produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain. 1997; 72(1-2): 253-260. DOI: 10.1016\/s0304-3959(97)00046-8.","DOI":"10.1016\/S0304-3959(97)00046-8"},{"key":"96945","doi-asserted-by":"crossref","unstructured":"Obara I, Mika J, Schafer MK, et al.: Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation. Br J Pharmacol. 2003; 140(3): 538-546. DOI: 10.1038\/sj.bjp.0705427.","DOI":"10.1038\/sj.bjp.0705427"},{"key":"96946","doi-asserted-by":"crossref","unstructured":"Nakagawa T, Wakamatsu K, Zhang N, et al.: Intrathecal administration of ATP produces long-lasting allodynia in rats: Differential mechanisms in the phase of the induction and maintenance. Neuroscience. 2007; 147(2): 445-455. DOI: 10.1016\/j.neuroscience.2007.03.045.","DOI":"10.1016\/j.neuroscience.2007.03.045"},{"key":"96947","doi-asserted-by":"crossref","unstructured":"Largent-Milnes TM, Guo W, Wang HY, et al.: Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain. 2008; 9(8): 700-713. DOI: 10.1016\/j.jpain.2008.03.005.","DOI":"10.1016\/j.jpain.2008.03.005"},{"key":"96948","doi-asserted-by":"crossref","unstructured":"Omara-Reda H, Ouachikh O, Hamdi D, et al.: Naltrexone promotes mechanical allodynia in humans and rats. Neurosci Lett. 2022; 786: 136816. DOI: 10.1016\/j.neulet.2022.136816.","DOI":"10.1016\/j.neulet.2022.136816"},{"key":"96949","doi-asserted-by":"crossref","unstructured":"Miller M, Barber CW, Leatherman S, et al.: Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015; 175(4): 608-615. DOI: 10.1001\/jamainternmed.2014.8071.","DOI":"10.1001\/jamainternmed.2014.8071"},{"key":"96950","doi-asserted-by":"crossref","unstructured":"Carrieri MP, Amass L, Lucas GM, et al.: Buprenorphine use: The international experience. Clin Infect Dis. 2006; 43(Suppl. 4): S197-S215. DOI: 10.1086\/508184.","DOI":"10.1086\/508184"},{"key":"96951","doi-asserted-by":"crossref","unstructured":"Webster LR: Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017; 125(5): 1741-1748. DOI: 10.1213\/ANE.0000000000002496.","DOI":"10.1213\/ANE.0000000000002496"},{"key":"96952","doi-asserted-by":"crossref","unstructured":"Dunn KE, Barrett FS, Fingerhood M, et al.: Opioid overdose history, risk behaviors, and knowledge in patients taking prescribed opioids for chronic pain. Pain Med. 2016; 18: 1505-1515. DOI: 10.1093\/pm\/pnw228.","DOI":"10.1093\/pm\/pnw228"},{"key":"96953","doi-asserted-by":"crossref","unstructured":"Chou R, Turner JA, Devine EB, et al.: The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015; 162(4): 276-286. DOI: 10.7326\/M14-2559.","DOI":"10.7326\/M14-2559"},{"key":"96954","doi-asserted-by":"crossref","unstructured":"Cheatle MD: Depression, chronic pain, and suicide by overdose: On the edge. Pain Med. 2011; 12(Suppl. 2): S43-S48. DOI: 10.1111\/j.1526-4637.2011.01131.x.","DOI":"10.1111\/j.1526-4637.2011.01131.x"},{"key":"96955","doi-asserted-by":"crossref","unstructured":"Madadi P, Persaud N: Suicide by means of opioid overdose in patients with chronic pain. Curr Pain Headache Rep. 2014; 18(11): 460. DOI: 10.1007\/s11916-014-0460-1.","DOI":"10.1007\/s11916-014-0460-1"},{"key":"96956","unstructured":"Wheeler E, Jones TS, Gilbert MK, et al.: Opioid overdose prevention programs providing naloxone to laypersons\u2014United States, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64(23): 631-635."},{"key":"96957","doi-asserted-by":"crossref","unstructured":"Ritter AJ: Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose. Aust N Z J Psychiatry. 2002; 36(2): 224-228. DOI: 10.1046\/j.1440-1614.2002.01012.x.","DOI":"10.1046\/j.1440-1614.2002.01012.x"},{"key":"96958","doi-asserted-by":"crossref","unstructured":"Pielech M, Lunde CE, Becker SJ, et al.: Comorbid chronic pain and opioid misuse in youth: Knowns, unknowns, and implications for behavioral treatment. Am Psychol. 2020; 75(6): 811-824. DOI: 10.1037\/amp0000655.","DOI":"10.1037\/amp0000655"},{"key":"96959","doi-asserted-by":"crossref","unstructured":"Eta SM: Pharmacological and behavioral treatment of opioid use disorder. Psychiatr Res Clin Pract. 2018; 1(1): 4-15. DOI: 10.1176\/appi.prcp.20180006.","DOI":"10.1176\/appi.prcp.20180006"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3891\/4176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3891\/4176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:55Z","timestamp":1755718495000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,20]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0891","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"type":"electronic","value":"1551-7489"},{"type":"print","value":"1551-7489"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}